Aqueous extracts of Portulaca oleracea L. alleviate atopic dermatitis by restoring skin barrier function
Open Access
- 5 June 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1591394
Abstract
Background: Portulaca oleracea L. (PO) is an edible plant with a long medicinal history in traditional Chinese medicine for various inflammatory diseases, including skin disorders such as atopic dermatitis (AD). However, the anti-inflammatory effects and AD-alleviating mechanisms of PO remain unclear.Methods: PO aqueous extract was prepared from a water-soluble portion and then mixed with carbomer to obtain a hydrogel, which provided stable drug permeation and absorption in mouse skin. Amantadine acetate was identified as an abundant ingredient and further predicted to be a Janus kinase 1 (JAK1) inhibitor via molecular binding simulation. Mice with AD, established by repeated sensitization with 2,4-dinitrochlorobenzene (DNCB), were topically treated with PO hydrogel. Aurantiamide acetate was applied to HaCaT keratinocytes prior to inflammatory challenge in the presence or absence of JAK1-siRNA. Transcriptional and translational gene expressions associated with cutaneous inflammation or skin barriers were assessed by qPCR and Western blotting, respectively. Enzyme-linked immunosorbent assays were performed to detect immunoglobulin E and proinflammatory factors in skin tissue or serum. The phosphorylation of JAK1, signal transducer and activator of transcription (STAT)3, and STAT6 in keratinocytes and skin were analyzed by Western blotting.Results: In DNCB-sensitized mice, the PO hydrogel ameliorated skin lesions, lowered symptom scores, and reduced epidermal thickness by suppressing proinflammatory factor generation, oxidative stress, and the expression of CD4+. The PO hydrogel promoted the expression of caspase-14 and filaggrin, thereby helping restore skin barrier function in AD. The PO hydrogel and/or aurantiamide acetate inhibited the enzymatic activity of JAK1 and downstream (STAT)3/STAT6 signaling pathways in vitro and in vivo.Conclusion: PO significantly ameliorated skin lesions and restored epidermal barrier function in AD mice. This was achieved by suppressing JAK1 enzymatic activity and JAK1-mediated STAT signaling pathways.Keywords
Funding Information
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
This publication has 33 references indexed in Scilit:
- Biomarkers in atopic dermatitisJournal of Allergy and Clinical Immunology, 2023
- Solid-in-oil nanodispersion as a novel topical transdermal delivery to enhance stability and skin permeation and retention of hydrophilic drugs l-ascorbic acidEuropean Journal of Pharmaceutics and Biopharmaceutics, 2023
- In vitro and in vivo exploration of the anti-atopic dermatitis mechanism of action of Tibetan medicine Qi-Sai-Er-Sang-Dang-Song decoctionJournal of Ethnopharmacology, 2023
- Overcoming skin barriers through advanced transdermal drug delivery approachesJournal of Controlled Release, 2022
- JAK inhibitors in the treatment of atopic dermatitisJournal of Allergy and Clinical Immunology, 2021
- A basophil-neuronal axis promotes itchCell, 2021
- Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochlorideJournal of Controlled Release, 2018
- Aurantiamide acetate from baphicacanthus cusia root exhibits anti-inflammatory and anti-viral effects via inhibition of the NF-κB signaling pathway in Influenza A virus-infected cellsJournal of Ethnopharmacology, 2017
- An in vivo and in vitro assessment of the anti-inflammatory, antinociceptive, and immunomodulatory activities of Clematis terniflora DC. extract, participation of aurantiamide acetateJournal of Ethnopharmacology, 2015
- Transdermal permeation of geniposide in the herbal complex liniment in vivo and in vitroInternational Journal of Pharmaceutics, 2010